Technical Analysis for AQST - Aquestive Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 6.95 10.49% 0.66
AQST closed up 10.49 percent on Monday, August 10, 2020, on 2.72 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical AQST trend table...

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Pharmaceutical Diseases Drugs Psychoactive Drugs Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Opioids Lactams Gabaa Receptor Positive Allosteric Modulators Parkinson’s Disease Neuroendocrine Tumors Riluzole

Is AQST a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 10.0
52 Week Low 1.41
Average Volume 774,512
200-Day Moving Average 4.73
50-Day Moving Average 5.14
20-Day Moving Average 5.28
10-Day Moving Average 5.74
Average True Range 0.40
ADX 33.61
+DI 41.41
-DI 7.83
Chandelier Exit (Long, 3 ATRs ) 5.90
Chandelier Exit (Short, 3 ATRs ) 5.20
Upper Bollinger Band 6.59
Lower Bollinger Band 3.98
Percent B (%b) 1.14
BandWidth 49.53
MACD Line 0.38
MACD Signal Line 0.20
MACD Histogram 0.1782
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.97
Resistance 3 (R3) 7.91 7.51 7.80
Resistance 2 (R2) 7.51 7.25 7.54 7.74
Resistance 1 (R1) 7.23 7.09 7.37 7.29 7.69
Pivot Point 6.83 6.83 6.90 6.86 6.83
Support 1 (S1) 6.55 6.57 6.69 6.61 6.21
Support 2 (S2) 6.15 6.41 6.18 6.16
Support 3 (S3) 5.87 6.15 6.10
Support 4 (S4) 5.93